Abstract: In a process for producing proteins with FVIII activity and FVIII derivatives by in vitro culturing of mammalian cells, the culturing is carried out at temperatures below 32.degree. C. and the culturing times used are below 24 hours.
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
March 4, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud E. Andersen, Per O. S.o slashed.rensen, Jesper Lau, Henning B. Petersen, Behrend F. Lundt
Abstract: The transfer of a textile dye from a dyed fabric to another fabric during washing or rinsing is inhibited by adding an enzyme exhibiting peroxidase activity or an enzyme exhibiting a suitable oxidase activity to the wash liquor in which said fabrics are washed and/or rinsed. Peroxidase is produced extracellularly by some strains of Bacillus pumilus. The novel peroxidase preparation from B. pumilus is a microperoxidase, i.e. it contains hemopeptide as an active component. The preparation has improved stability at high temperature, at high pH and at high concentrations of hydrogen peroxide. It can be produced without undesired catalase activity.
Type:
Grant
Filed:
August 11, 1993
Date of Patent:
February 25, 1997
Assignees:
Novo Nordisk A/S, The Proctor & Gamble Company
Inventors:
Ture Damhus, Ole Kirk, Gitte Pedersen, Manuel G. Venegas
Abstract: The present invention relates to a process for preparing a triglyceride, comprising reacting glycerol with a polyunsaturated fatty acid having at least 20 carbon atoms and at least three double bonds or a C.sub.1-4 alkyl ester thereof, for a reaction time in the range of 24-48 hours at a temperature between 40.degree. and 80.degree. C. in the presence of a mixture of lipase A and lipase B obtained from Candida antarctica which is immobilized, to form (i) the triglyceride and (ii) water or a C.sub.1-4 alcohol, while removing the water or the C.sub.1-4 alcohol during the reaction, and recovering the triglyceride.
Type:
Grant
Filed:
January 23, 1995
Date of Patent:
February 18, 1997
Assignees:
Novo Nordisk A/S, LYSI HF
Inventors:
Gudmundur G. Haraldsson, Hanne Svanholm, Baldur Hjaltason
Abstract: The present invention relates to therapeutically active azaheterocyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating a central nervous system ailment related to the GABA uptake.
Type:
Grant
Filed:
June 22, 1994
Date of Patent:
February 18, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Hans Petersen, Knud E. Andersen, Per O. S.o slashed.rensen, Jesper Lau, Behrend F. Lundt
Abstract: The present invention relates to recombinant thermophilic host cells comprising a nucleic acid sequence encoding a heterologous protein, and a method of producing recombinant protein utilizing same. The recombinant hosts of the present invention provide a better morphology in tank fermentations than many known fungal host cells, such as Aspergillus, which morphology results in lower viscosity levels, and therefore improved productivity.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
February 18, 1997
Assignee:
Novo Nordisk Biotech, Inc.
Inventors:
Ejner B. Jensen, Karuppan C. Boominathan
Abstract: The present invention relates to recombinant thermophilic host cells comprising a nucleic acid sequence encoding a heterologous protein, and a method of producing recombinant protein utilizing same. The recombinant hosts of the present invention provide a better morphology in tank fermentations than many known fungal host cells, such as Aspergillus, which morphology results in lower viscosity levels, and therefore improved productivity.
Type:
Grant
Filed:
July 20, 1994
Date of Patent:
February 11, 1997
Assignee:
Novo Nordisk Biotech, Inc.
Inventors:
Ejner B. Jensen, Karuppan C. Boominathan
Abstract: The method for cleaning of heat exchangers after passage of fluid, pulpy material through the heat exchangers is characterized by the fact that the heat exchangers are exposed to a cip (cleaning in place) treatment with a solution of an enzyme preparation, which contains pectolytic, cellulolytic and hemicellulolytic activities. This method for cleaning of heat exchangers is less time and energy consuming and more environmental-friendly than the hitherto used methods of this kind.
Abstract: An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G 30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 .mu.m.
Type:
Grant
Filed:
October 30, 1995
Date of Patent:
February 4, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Frits F. Bonnichsen, Peter N. J.o slashed.rgensen
Abstract: Insulin analogues have been developed which are well suited for transdermal administration by iontophoresis. The insulin analogues have a negative charge at neutral pH and a reduced tendency to association. They are prepared by altering the human insulin molecule by substituting at least two of the amino acid residues of human insulin by Glu and/or Asp at selected positions in the molecule.
Abstract: An alkaline protease has been isolated from Bacillus sp. PD 498 which has a mass of 34 kD by SDS-PAGE, a pH optimum of 9-11, a pI of 9.3, and a temperature optimum of 40.degree.-55.degree. C. The protease has been formulated into detergent additives and detergents and is suitable for washing processes.
Type:
Grant
Filed:
October 26, 1994
Date of Patent:
January 28, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Helle Outtrup, Claus Dambmann, Dorrit A. Aaslyng
Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
Type:
Grant
Filed:
January 3, 1995
Date of Patent:
January 21, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Knud E. Andersen, Uffe B. Olsen, Hans Petersen, Frederik Gr.o slashed.nvald, Ursula Sonnewald, Tine K. J.o slashed.rgensen, Henrik S. Andersen
Abstract: Compounds having formula (3), wherein R.sup.1 is hydrogen, straight or branched alkyl with 1-10 carbon atoms, straight or branched alkenyl with 2-10 carbon atoms, straight or branched alkynyl with 2-10 carbon atoms, benzyl or aryl, optionally mono- or plurisubstituted with straight or branched alkyl with 1-10 carbon atoms, hydroxy, alkoxy, halogen, an amino or a nitro group; and when R.sup.1 is H salts thereof, or R.sup.1 is acyl (R.sup.1 =--COR.sup.2) wherein R.sup.2 is straight or branched alkyl with 1-10 carbon atoms, alkenyl with 2-10 carbon atoms, alkynyl with 2-10 carbon atoms, or aryl, optionally mono- or plurisubstituted with alkyl with 1-10 carbon atoms, hydroxy, alkoxy, halogen, an amino or a nitro group. Compounds of formula (3) have interesting antifungal activities and may, accordingly, be used as active ingredients in fungicidal compositions.
Abstract: The present invention relates to a gene encoding an ascomycete or deuteromycete carboxypeptidase Y gene, and host cells modified so as to produce reduced amounts of carboxypeptidase.
Abstract: The present invention relates to therapeutically active azacyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful as stimulants of the cognitive function of the forebrain and hippocampus of mammals and especially in the treatment of Alzheimer's disease, severe painful conditions and glaucoma.
Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.
Type:
Grant
Filed:
June 23, 1993
Date of Patent:
January 7, 1997
Assignee:
Novo Nordisk A/S
Inventors:
Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR1## wherein X is halogen, amino, perhalomethyl, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino;A is methyl, halomethyl, cyanomethyl, aminomethyl, vinyl, methylthiomethyl or methoxymethyl;R.sup.1 is selected from optionally substituted N-bonded heterocyclics.The compounds have been found useful for treating central nervous system ailments.
Abstract: The present invention relates to rhamnogalacturon acetyl esterases derived from Aspergillus aculeatus and DNA Sequences encoding the enzymes. The present invention also relates to the use of rhamnogalacturon acetyl esterases for degrading modified hairy region.
Type:
Grant
Filed:
October 5, 1994
Date of Patent:
December 17, 1996
Assignee:
Novo Nordisk A/S
Inventors:
Kurt Dorreich, Flemming M. Christensen, Yvette Schnell, Marcel Mischler, Henrik Dalb.o slashed.ge, Hans P. Heldt-Hansen
Abstract: This application relates to modified blood coagulation factors, DNA sequences coding for such modified factors and a process for their production.
Type:
Grant
Filed:
August 22, 1994
Date of Patent:
December 3, 1996
Assignee:
Novo Nordisk A/S
Inventors:
Else M. Nicolaisen, S.o slashed.ren E. Bj.o slashed.rn, Finn C. Wiberg, Richard Woodbury